News | October 22, 2012

Resource Helps Advance Understanding of Cardiac Side Effects from Chemotherapy

October 22, 2012 — QuantiaMD, the largest online physician community, and The International CardiOncology Society (ICOS) announced at the ICOS 6th annual meeting in Milan, Italy a partnership to launch the ICOS global physicians collaboration forum on QuantiaMD. This first-of-its-kind partnership brings together an emerging area of medicine with QuantiaMD’s dynamic clinical exchange to rapidly drive awareness, education and training around the cardiac implications of oncology treatments.

ICOS was founded in 2009 by Dr. Carlo Cipolla (European Institute of Oncology, Milan, Italy) and Daniel Lenihan (while at MD Anderson Cancer Center, Houston, Texas) with a goal of eliminating cardiac disease as a barrier to optimal cancer therapy. Previously thought to be a relatively rare phenomenon, studies done by Cipolla and Lenihan suggest that as high as 20-30 percent of patients receiving certain classes of anticancer therapies may have some level of cardiac side effects. Cancer therapeutics, both radiation therapy and chemotherapy, are known to have important effects on the cardiovascular system. Many of these long-term consequences did not become clinically evident until overall cancer survival improved enough for the effects to be realized.

ICOS is leveraging QuantiaMD’s extensive physician membership, and its breakthrough media and communications platform, to engage clinicians via mobile devices and the web. QuantiaMD and ICOS are producing a series of concise, interactive patient cases and other resources, which QuantiaMD will distribute broadly to engage and educate all relevant clinicians. In addition, QuantiaMD’s leading technology platform is enabling new and effective ways of collaborating across this global group of oncologists and cardiologists from top centers such Vanderbilt, MD Anderson and Memorial Sloan Kettering. Presentations, including audio and PowerPoint from the 6th Annual Meeting, will be placed on QuantiaMD as soon as available, and previous proceedings of the Annual Meeting are already available.

Cardiac side effects, such as heart failure, can prevent patients from continuing to receive optimal cancer treatments, as well as impact long-term survival. “Many cardiac side effects can be more effectively managed, and, in some cases, prevented, with currently available therapies,” said Lenihan. “Much more investigation is needed, but it is critical that we raise the awareness among oncologists and cardiologists to ensure optimal management of these patients.”

There are no currently established medical guidelines for the care of adults who have survived cancer therapy, particularly as it relates to heart disease, and, specifically heart failure. Lenihan is using QuantiaMD’s secure Clinical Discussion feature to draft and refine the first set of clinical guidelines on this important topic, soliciting input from members of many professional societies including the Heart Failure Society of America, American College of Cardiology, European Society of Medical Oncology, American Society of Clinical Oncology and the European Society of Cardiology. In addition, ICOS will leverage QuantiaMD to disseminate important new data being released during its annual meeting as well as help to support clinical trial centers become more connected in the future.

“Traditional web approaches have not adequately expressed or augmented the dynamism of medical practice and research,” said Eric Schultz, chairman and CEO of QuantiaMD. “With ICOS, we hope to set a new paradigm for how physicians learn and collaborate within a secure environment in critical areas of patient care.”

For more information: www.cardioncology.com

 

Related Content

UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
PET/CT

The Philips Ingenuity TF PET/CT system leverages multiple technologies.

Feature | Radiation Oncology | May 05, 2017 | By Lola Koktysh
The continuum of personalized care, covering individualized prevention and therapy, translates into multiple changes to...
Guided Therapeutics, LuViva Advanced Cerivcal Scan, first to Russia, cervical cancer
News | Oncology Diagnostics | August 24, 2016
August 24, 2016 — Guided Therapeutics Inc.
LiverMultiScan, liver disease diagnosis, children, pediatric patients, U.K., Poland, Kids4LIFe consortium
News | Oncology Diagnostics | July 27, 2016
A U.K-Poland consortium was recently awarded a €1.1M grant to develop a magnetic resonance imaging (MRI)-based medical...
News | Oncology Diagnostics | July 27, 2016
Cubresa Inc. announced the United States Patent and Trademark Office has issued a U.S. patent for a novel arrangement...
metastatic prostate cancer incidence, Northwestern Medicine study, Edward Schaeffer, Adam Weiner
Feature | Prostate Cancer | July 25, 2016
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports...
PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016
Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
NSCLC, lung cancer, chemotherapy, FDG PET, SNMMI 2016
News | PET Imaging | June 22, 2016
Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy....
News | Oncology Diagnostics | May 25, 2016
Scientists are developing a new photonics device that listens to light and could be capable of detecting skin cancer...
Overlay Init